Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Free Report) have earned an average rating of “Moderate Buy” from the eight research firms that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating on the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $35.71.
Several analysts have commented on DAWN shares. Needham & Company LLC raised their target price on shares of Day One Biopharmaceuticals from $32.00 to $33.00 and gave the stock a “buy” rating in a report on Wednesday. Piper Sandler reaffirmed an “overweight” rating and issued a $40.00 price objective on shares of Day One Biopharmaceuticals in a research report on Monday, July 8th. Wedbush reissued an “outperform” rating and issued a $33.00 price target on shares of Day One Biopharmaceuticals in a research note on Thursday, July 25th. Bank of America upgraded Day One Biopharmaceuticals from an “underperform” rating to a “buy” rating and increased their price objective for the stock from $11.00 to $24.00 in a report on Thursday, August 1st. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $40.00 target price on shares of Day One Biopharmaceuticals in a research report on Thursday, August 1st.
View Our Latest Report on Day One Biopharmaceuticals
Insiders Place Their Bets
Hedge Funds Weigh In On Day One Biopharmaceuticals
A number of hedge funds have recently bought and sold shares of DAWN. Deerfield Management Company L.P. Series C raised its holdings in shares of Day One Biopharmaceuticals by 65.6% during the second quarter. Deerfield Management Company L.P. Series C now owns 2,923,137 shares of the company’s stock valued at $40,281,000 after purchasing an additional 1,157,825 shares during the period. Estuary Capital Management LP boosted its holdings in Day One Biopharmaceuticals by 82.5% in the first quarter. Estuary Capital Management LP now owns 1,611,137 shares of the company’s stock worth $26,616,000 after acquiring an additional 728,240 shares in the last quarter. Ally Bridge Group NY LLC acquired a new stake in Day One Biopharmaceuticals in the second quarter valued at approximately $7,387,000. Braidwell LP increased its holdings in shares of Day One Biopharmaceuticals by 13.5% during the fourth quarter. Braidwell LP now owns 4,215,573 shares of the company’s stock valued at $61,547,000 after acquiring an additional 500,000 shares in the last quarter. Finally, Goldman Sachs Group Inc. raised its position in shares of Day One Biopharmaceuticals by 28.7% during the fourth quarter. Goldman Sachs Group Inc. now owns 2,118,849 shares of the company’s stock worth $30,935,000 after purchasing an additional 472,654 shares during the period. Institutional investors own 87.95% of the company’s stock.
Day One Biopharmaceuticals Stock Up 2.6 %
DAWN opened at $13.88 on Wednesday. The stock has a market cap of $1.22 billion, a P/E ratio of -7.12 and a beta of -1.51. Day One Biopharmaceuticals has a 12 month low of $9.67 and a 12 month high of $18.07. The company has a fifty day simple moving average of $13.88 and a 200 day simple moving average of $14.43.
Day One Biopharmaceuticals (NASDAQ:DAWN – Get Free Report) last announced its quarterly earnings results on Tuesday, July 30th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.75) by $0.70. The business had revenue of $8.19 million during the quarter, compared to the consensus estimate of $0.90 million. On average, equities research analysts expect that Day One Biopharmaceuticals will post -1.68 earnings per share for the current fiscal year.
Day One Biopharmaceuticals Company Profile
Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.
Read More
- Five stocks we like better than Day One Biopharmaceuticals
- Why Invest in High-Yield Dividend Stocks?
- 3 Micro-Caps Set for Major Moves: Balancing Risk and Opportunity
- Earnings Per Share Calculator: How to Calculate EPS
- Autodesk Named a “Top Pick” by Morgan Stanley—Is It Time to Buy?
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- 4 Quirky ETFs With Big Potential for Impressive Gains
Receive News & Ratings for Day One Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Day One Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.